Sinopharm Chuankang Pharmaceutical

Sinopharm Chuankang Pharmaceutical is a China-based pharmaceutical manufacturer focused on immunosuppressants, oncology-related therapies, and select oral solid and liquid formulations. The company is a subsidiary within the Sinopharm group, under Shanghai Shyndec Pharmaceutical, and operates GMP-certified API and oral dosage manufacturing facilities in Chengdu, Sichuan. Publicly described core products include tacrolimus, mycophenolate mofetil, cyclosporine, midodrine hydrochloride, mannatide, and ubenimex, indicating a business centered on marketed products and lifecycle management rather than a novel-discovery biotech pipeline. Available evidence points to commercial-stage operations with some recent bioequivalence and formulation-development work, including tacrolimus extended-release capsules and iguratimod tablets. The company appears to serve the Chinese market primarily through manufacturing, development, and commercialization of established pharmaceutical products.